Savient Pharmaceuticals slips on a Q2 EPS miss

Savient Pharmaceuticals (SVNT -5%) slips after its Q2 misses EPS estimates on a greater than anticipated loss.

Net revenues increased by 44% Y/Y to $2.1M, primarily driven by higher KRYSTEXXA net sales.

KRYSTEXXA net sales rose 52% Y/Y, substantially due to the impact of product price increases and to a lesser extent an increase in sales volume.

The selling price of KRYSTEXXA increased by approximately 134% from the original list price of $2,300 per vial to the current list price of $5,390 per vial, effective May 17, while 2,058 vials of KRYSTEXXA were sold, an increase of 9% Y/Y.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs